This article is for educational purposes only. CJC-1295 and Ipamorelin are research peptides. Consult a physician before use, especially if you have a history of cancer, active acromegaly, or are on insulin therapy. IGF-1 monitoring is recommended during extended cycles.
Growth hormone (GH) is secreted by the pituitary gland in a pulsatile pattern — not continuously. The largest GH pulse occurs during slow-wave (deep) sleep, typically 60–90 minutes after falling asleep. Daytime pulses occur throughout the day but are smaller.
GH secretion is regulated by two hypothalamic hormones acting in opposition: GHRH (Growth Hormone-Releasing Hormone), which stimulates GH release, and somatostatin, which inhibits it. The natural GH pulse occurs when GHRH surges while somatostatin is low.
GH levels begin declining around age 30 at approximately 14–15% per decade — a phenomenon called somatopause. By age 60, most people have lost 60–70% of their youthful GH pulsatility. This decline tracks directly with the body composition changes, recovery decline, sleep deterioration, and skin aging that characterize middle age.
The CJC-1295 + Ipamorelin stack works by amplifying the pituitary's own GH release rather than replacing GH — preserving the natural feedback mechanisms that keep GH levels in the physiological range.
| Parameter | CJC-1295 without DAC (Mod GRF 1-29) |
|---|---|
| Type | GHRH analogue — stimulates hypothalamic GHRH receptors on pituitary somatotrophs |
| Half-life | ~30 minutes (without DAC) — produces a defined, physiological GH pulse |
| Mechanism | Binds GHRH receptors → cAMP cascade → GH synthesis and release from pituitary somatotrophs |
| Standard dose | 100–200 mcg per injection |
| Timing | Bedtime, on empty stomach (2+ hours after last meal). Also: pre-workout or morning fasted. |
| Effect on GH | Amplifies GH pulse amplitude — increases peak GH output from each natural pulse |
CJC-1295 is a modified version of the first 29 amino acids of GHRH (Growth Hormone-Releasing Hormone) with substitutions at positions 2, 8, 15, and 27 that dramatically increase its stability and resistance to enzymatic degradation while preserving full receptor binding activity.
The short half-life of CJC-1295 without DAC (~30 minutes) is actually a desirable feature — it produces a defined, physiological GH pulse rather than sustained GH elevation, which better mimics the natural pulsatile pattern and avoids receptor desensitization.
| Parameter | Ipamorelin |
|---|---|
| Type | GHRP (Growth Hormone-Releasing Peptide) — ghrelin mimetic |
| Half-life | ~2 hours |
| Mechanism | Binds GHSR-1a (ghrelin receptor) → activates GH release pathway; simultaneously suppresses somatostatin → removes the brake on GH release |
| Standard dose | 100–200 mcg per injection |
| Timing | Bedtime, on empty stomach. Synchronized with CJC-1295. |
| Effect on GH | Releases the somatostatin brake + stimulates GH release — works via completely different mechanism from CJC-1295 |
| Key advantage over GHRP-6 | Ipamorelin does not cause cortisol or prolactin elevation — making it the cleanest GHRP available |
Ipamorelin is a pentapeptide ghrelin mimetic — it activates the same GH secretagogue receptor (GHSR-1a) as the hunger hormone ghrelin, but without ghrelin's appetite-stimulating and cortisol-raising effects. This selectivity for GH release without off-target effects makes Ipamorelin the preferred GHRP in most optimization protocols.
Crucially, Ipamorelin works through a completely different mechanism than CJC-1295 — it suppresses somatostatin (the GH inhibitor) while also directly triggering GH release. When combined with CJC-1295, the result is a simultaneous hit on both the accelerator and the brake of GH secretion.
When CJC-1295 and Ipamorelin are administered simultaneously, they produce GH pulses that are 3–6 times greater than either peptide alone. CJC-1295 maximizes the GH release signal from the pituitary. Ipamorelin simultaneously removes somatostatin's inhibitory brake. The result is a perfectly timed, physiologically patterned GH surge that mirrors — and amplifies — the natural bedtime GH pulse.
This is the most common source of confusion in GH peptide protocols. There are two forms of CJC-1295:
| CJC-1295 without DAC (Mod GRF 1-29) | CJC-1295 with DAC | |
|---|---|---|
| Half-life | ~30 minutes | 6–8 days |
| GH release pattern | Defined physiological pulse | Sustained, continuous GH elevation ("GH bleed") |
| Dosing frequency | 1–3x daily at each injection session | Once or twice weekly |
| Receptor desensitization | Minimal — pulsatile pattern prevents downregulation | Higher risk with chronic use |
| For stacking with Ipamorelin | ✓ Recommended — produces synchronized pulses | Less ideal — mismatch in action profiles |
| Best for | Body composition, recovery, sleep optimization | Convenience (weekly injection); anti-aging maintenance |
For the CJC-1295 + Ipamorelin stack, always use CJC-1295 without DAC (Mod GRF 1-29). The short half-life synchronizes perfectly with Ipamorelin's action window, producing a clean physiological GH pulse. CJC-1295 with DAC produces chronic GH elevation that blunts the natural pulsatile pattern and increases receptor desensitization risk over time.
| Parameter | Standard Protocol |
|---|---|
| CJC-1295 (no DAC) dose | 100–200 mcg per injection |
| Ipamorelin dose | 100–200 mcg per injection |
| Injection frequency | Once daily (bedtime) for most users; advanced: add a morning fasted injection (2x/day) |
| Timing | Bedtime, minimum 2 hours after last meal. Empty stomach is critical — insulin from recent food intake blunts GH release. |
| Injection method | Both peptides can be drawn into the same syringe and administered as one injection (compatible) |
| Schedule | 5 days on / 2 days off — allows pituitary receptor recovery and prevents desensitization |
| Cycle length | 12–16 weeks followed by 4–8 weeks off |
Both peptides come as lyophilized powder and require reconstitution with bacteriostatic water:
| Phase | Schedule | Notes |
|---|---|---|
| Active cycle | 12–16 weeks, 5 days on / 2 days off | Weekends off is most common. Allows receptor recovery. |
| Off cycle | 4–8 weeks minimum | IGF-1 levels normalize. GH axis recovers fully. Monitor IGF-1 at end of cycle. |
| Cycles per year | 2–3 cycles | With 4–6 weeks off between each |
| Maintenance option | Single bedtime injection, 3 nights/week | Lower-intensity continuous use for general longevity maintenance without full cycling concern |
| Added Compound | Purpose | Synergy |
|---|---|---|
| BPC-157 | Tissue repair | GH elevates IGF-1, which synergizes with BPC-157's healing mechanisms. Classic body recomposition + recovery stack. |
| AOD-9604 | Fat loss | GH fragment specifically targeting lipolysis. Stacking with CJC/Ipa amplifies fat loss without the growth-promoting effects of full GH. |
| Sermorelin | Alternative GHRH | Can substitute for CJC-1295 if unavailable; shorter half-life, less potent. Not as effective as the CJC/Ipa combo. |
| DSIP | Sleep enhancement | Compounds CJC/Ipa's sleep architecture improvement; delta sleep peptide amplifies slow-wave sleep where GH pulse occurs. |
| NMN + TMG | Longevity | NAD+ optimization complements GH-mediated IGF-1 signaling. Comprehensive longevity + performance stack. |
CJC-1295 + Ipamorelin is among the most widely used peptide combinations in anti-aging medicine with a favorable safety record when used at recommended doses:
No — and this is a critical distinction. Exogenous HGH injections bypass the pituitary and suppress the body's own GH production via negative feedback. Long-term HGH use can cause pituitary atrophy. CJC-1295 + Ipamorelin stimulates your own pituitary to produce GH — the natural feedback loop remains intact. This means no pituitary suppression, physiological GH levels, and a much safer side effect profile than pharmaceutical HGH.
Most users report improved sleep quality and recovery within the first 1–2 weeks. Subjective body composition changes (reduced body fat, improved muscle tone) are typically noticeable at weeks 4–8. Skin quality improvements — often described as a "glow" — appear at weeks 6–12. Measurable IGF-1 elevation confirms GH axis activation at weeks 4–6.
Yes — women respond well to GH secretagogues. Women naturally have higher GH pulse frequency than men (though lower amplitude). Standard dosing applies. Women may notice enhanced skin quality, body composition, and recovery. Note that GH modestly influences estrogen metabolism — discuss with your physician if on hormone therapy.
Yes — this is the most commonly used body recomposition stack in anti-aging medicine. GH + testosterone produce synergistic anabolic and fat loss effects. Under physician supervision only. IGF-1 and testosterone monitoring required.
Log both peptides, monitor IGF-1 trends, track body composition changes, and get AI-powered protocol optimization from the Health Intelligence Advisor. Founding member pricing locked at launch.
Join the Waitlist →